Add this topic to your myFT Digest for news straight to your inbox
Older inactivated virus technology in domestic shots less effective against infection than foreign rivals
Despite dispensing 2.5bn doses, recent outbreaks raise uncertainty over Sinovac and Sinopharm jabs
Biotech’s jab could give the technology a boost amid concerns over efficacy of conventional shots
Officials insist jabs work but lack of peer-reviewed research reinforces doubts about efficacy
City has gambled on keeping its border open to the world during the pandemic
Authorisation allows jab to be deployed by Covax in boost for Chinese pharma industry
Top health official says remarks about jabs were ‘taken out of context’
Disease control centre makes first public admission over effectiveness of domestic jabs
Julphar deal with G42 will allow Gulf state to accelerate global supply plan
Concerns over transparency, efficacy and supply weaken global demand for country’s Covid-19 jabs
Sinopharm booster given to small number of people who have shown weak immunity after two doses
China’s state-backed pharmaceutical group is trying to sign up governments for its jab
Budapest also orders Russia-made shot despite lack of approval for use within bloc
International travel restrictions expected until next year
Covid vaccine maker wants to take China TCM private; the timing is right
Sinopharm claims 79% efficacy but concerns remain over lack of trial data transparency
Pharma company will seek approval from regulator as it looks to distribute jab more widely
Emirati government wants to inoculate all adults in population of 9m against Covid-19
Experts worry that doubts about data threaten to undermine immunisation efforts
Health ministry says its studies show similar results to pharma group’s interim analysis of phase 3 trial
Rules limiting number of invoices between drugmakers and hospitals to be rolled out
International Edition